In the field of antibody development, the term "screening" usually evokes thoughts of in vitro techniques such as hybridoma screening or phage display after animal immunization. However, this article delves into a more fundamental and critical question: How are high-quality antibodies naturally selected within the immune system?
Without understanding the internal logic of the immune system's natural screening, it is difficult to explain why certain antigens struggle to induce high-quality antibodies. Nor can one clearly understand how booster immunizations, antigen design optimization, or adjusted immunization strategies alter key biological links. These immunological principles provide vital theoretical guidance and serve as the core foundation for the VHH antibody Discovery Service at AlpVHHs when designing immune design protocols and optimizing antibody affinity.
A common question is: Do receptors for a specific antigen already exist in the body before immunization? The answer is yes. Cell receptor diversity is established during the developmental stages of lymphocytes through gene rearrangement mechanisms, rather than being generated on-the-fly upon antigen entry. This pre-established, massive receptor repertoire lays a solid foundation for the subsequent immune response.
The diversity of B-cell and T-cell receptors stems from two core mechanisms: Combinatorial diversity and Junctional diversity.
At the combinatorial level, different V (variable), D (diversity), and J (joining) gene segments are randomly selected and rearranged through V(D)J recombination. Theoretically, the maximum number of combinations for a single receptor locus equals the product of the number of V, D, and J segments, roughly between 106 and 3 × 106. Furthermore, random pairing between chains—such as immunoglobulin heavy and light chains, or TCR α and β chains—significantly amplifies the potential diversity.
The key to exponentially expanding diversity lies in Junctional diversity. In the V-D, D-J, or V-J junction regions, nucleotide sequences can be precisely deleted, modified by adding P-nucleotides, or randomly inserted with up to 20 non-templated N-nucleotides. This highly stochastic process makes the CDR3 region the most variable part of the entire receptor molecule. The number of amino acid sequences CDR3 can form far exceeds the coding capacity of the germline genes, making it the most critical determinant of antigen-binding specificity and affinity.
This mechanism is equally significant in VHH development, as VHH CDR3s are typically longer and structurally flexible, providing unique advantages for recognizing cryptic epitopes.
Despite a staggering theoretical scale, the number of functional B and T cell receptors actually expressed in the human body at any given time is maintained at approximately 107. This scale is limited by strict positive selection, negative selection, and functional screening during lymphocyte development. Many potential receptors are eliminated due to excessive self-reactivity or failure to assemble correctly.
This means the immune system does not blindly produce infinite diversity; instead, it prepares a massive, pre-screened candidate library. The ultimate quality of an antibody is determined not by the absolute quantity of initial diversity, but by the subsequent multi-layered selection and optimization driven by the antigen.
Antigens do not create entirely new receptors; their core role is to initiate competition, activation, and selection within the existing repertoire. In a typical T-cell-dependent immune response induced by protein antigens, the process is divided into an initial emergency phase and a subsequent maturation phase.
The immune response begins in secondary lymphoid organs. B cells recognize conformational epitopes of native protein antigens via their BCRs, while CD4+ helper T cells are activated by linear peptides presented by dendritic cells. Activated lymphocytes migrate toward each other and interact at the boundary of T and B cell zones.
In this phase, some activated B cells proliferate rapidly in the extrafollicular area, undergoing isotype switching and differentiating into mostly short-lived plasma cells. This extrafollicular response provides rapid defense during the early stages of invasion, but the overall affinity is usually low and has not yet undergone systemic optimization.
Approximately 4–7 days after the start of the immune response, some activated B cells and T follicular helper (Tfh) cells migrate back into the lymphoid follicles to form the germinal center. The germinal center is essentially a B-cell evolution and screening system meticulously guided by Tfh cells.
In the "Dark Zone," B cells proliferate at high speeds and undergo somatic hypermutation (SHM) mediated by AID, generating numerous mutant clones with varying affinities. These clones then migrate to the "Light Zone," where they interact with antigens presented by Follicular Dendritic Cells (FDCs) and survival signals from Tfh cells. Only B cells expressing receptors with the highest affinity receive survival signals; the rest are eliminated via apoptosis.
Activated B cells migrate into the lymphoid follicles and rapidly proliferate, forming the dark zone of the germinal center. In the dark zone, these B cells undergo somatic hypermutation (SHM) of their immunoglobulin (Ig) V genes. They subsequently migrate to the light zone, where they interact with antigen-presenting follicular dendritic cells (FDCs) and T follicular helper cells (Tfh cells).
B cells expressing the highest-affinity Ig receptors are selectively retained and survive. They then differentiate into antibody-secreting cells and memory B cells. The antibody-secreting cells exit the germinal center and migrate to the bone marrow, where they become long-lived plasma cells. Memory B cells enter the circulating lymphocyte pool and persist for long periods in the body.
This "mutation-selection" cycle is the core mechanism of Affinity Maturity. It provides the direct theoretical basis and methodology for the AlpVHHs VHH affinity optimization platform to improve nanobody affinity through in vitro simulated mutation and selection.
Why do B cells require T-cell help? The fundamental reason is that in T-cell-dependent responses, B and T cells recognize different epitopes of the same antigen. B cells internalize the antigen via BCR, process it into linear peptides, and present them via MHC II to helper T cells. This cooperative mechanism ensures the specificity and efficiency of the immune response and provides a natural template for screening high-specificity VHH clones.
Despite these efficient mechanisms, some antigens remain challenging. Reasons include extremely low precursor B-cell frequency for key functional epitopes, masking of important epitopes by immunodominant regions, insufficient T-cell help, or weak selection pressure within the germinal center.
The AlpVHHs VHH antibody Discovery Service is based on a deep understanding of these immunological bottlenecks, utilizing diverse immune design strategies and optimized antigen designs to systematically overcome these challenges.
Antibodies are not simply "engineered"; they are optimized through layers of rigorous selection pressure from a massive, random receptor repertoire. At AlpVHHs, we translate these classical immunological principles into practical antibody development operations, providing high-affinity, high-specificity, and application-ready nanobodies. And we have partnered with more than 300 biotechnology companies, biopharmaceutical firms, and academic institutions, successfully completing over 1500+ sdAb pre-discovery projects. Notably, more than 25+ collaborative programs have advanced to IND (Investigational New Drug) approval.
VHH Library (High-Affinity): Providing nanobody libraries covering massive receptor diversity.
Customized Immunization Services: Efficiently producing high-specificity antibodies based on T-cell-dependent strategies.
Antibody Screening & Selection: Simulating natural multi-level screening to pick the best VHH clones.
VHH Affinity Optimization Platform: Achieving Affinity Maturity through in vitro mutation and selection cycles.
